Tern’s portfolio company Wyld Networks signs contract with Bayer Crop Science

IoT

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has noted that its portfolio company Wyld Networks AB has announced that it has signed a contract with Bayer Crop Science, a world leader in agriculture and part of the multinational Bayer Corporation.  Bayer has placed an initial purchase order worth SEK 320,000 (approximately £27,000) with Wyld Networks to develop a satellite IoT terminal and sensor to collect data from beehives.

Commenting Al Sisto, CEO of Tern, said:

“This is an important engagement for Wyld and we are very pleased that they are now working to develop a satellite IoT platform with Bayer. As Wyld’s CEO Alastair Williamson has pointed out, there is a substantial and growing market for affordable satellite IoT connectivity in multiple markets from agriculture, utilities, maritime and the environment and we look forward to Wyld’s continued progress”.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search